Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 557

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 557
---
. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, professional fees for accounting, tax and consulting services, insurance costs, travel expenses and facility related expenses not otherwise included in research and development expenses.

We expect our general and administrative expenses may increase for the foreseeable future if and as we continue to increase our general and administrative headcount to support our continued research and development activities and, if any product candidates receive marketing approval, commercialization activities, as well as to support our operations generally. We also expect to continue to incur increased expenses associated with operating as a public company, including costs related to accounting, audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and rules and regulations of the Securities and Exchange Commission (“SEC”), Sarbanes-Oxley Act, director and officer insurance costs, and investor and public relations costs.

Amortization of intangible asset

Amortization of intangible asset relates to the technology acquired in the BioArkive acquisition. 

Other Income (Expense)

Interest income

Interest income consists of interest earned on our cash and cash equivalents balances and our marketable securities. The primary objective of our investment policy is capital preservation.

Other income (expense)

Other income (expense) consists of the amortization of premiums or accretion of discounts related to our marketable securities.

32

Table of Contents

Results of Operations

Comparison of the Three Months Ended September 30, 2025 and 2024

The following table summarizes our results of operations for the periods indicated:

Three Months Ended September 30,Change20252024$% (in thousands, except percentages)Operating expensesResearch and development$10,868 $11,253 $(385)(3.4)%General and administrative4,505 4,014 491 12.2 %  Amortization of intangible asset7 7 — — %Total operating expenses15,380 15,274 106 0.7 %Loss from operations(15,380)(15,274)(106)0.7 %Other income (expense)Interest income416 547 (131)(23.9)%Other income, net— 129 (129)(100.0)%Net loss$(14,964)$(14,598)$(366)2.5 %

Research and Development

The following table summarizes the components of our research and development expenses for the periods indicated:

Three Months Ended September 30,Change202